Data from EMC - Curated by EPG Health - Last updated 19 August 2016
Indication(s)
Hydrocortistab Injection is indicated for the local treatment, by intra-articular or periarticular injection, of arthritic conditions such as rheumatoid arthritis and osteoarthritis when few joints are involved. It is also suitable for the symptomatic treatment, by local injection, of certain non-articular inflammatory conditions such as inflamed tendon sheaths and bursae.
Hydrocortistab Injection is not suitable for the production of systemic effects.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Migraine Knowledge Centre
The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.
Chronic Obstructive Pulmonary Disease (COPD)
View highlights from recent congresses presented in new expert videos with leading physicians.
+ 7 more
Acute and Advanced Heart Failure
What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...
+ 3 more
Allergic Rhinitis
Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.
+ 4 more
Atopic Dermatitis
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Inflammatory bowel disease assessment tools
'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.
Chronic Spontaneous Urticaria (CSU)
Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.
+ 7 more
Related Content
Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis (EQUIRA)
Demonstrate equivalent efficacy of GP2015 and EU-authorized Enbrel in patients with moderate to severe, active (RA) who had an inadequate response to disease modifying anti-rheumatic drugs (DMARD) including methotrexate (MTX).
Added 7 months ago
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (C-AXSPAND)
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo.
Added 6 months ago
A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (SELECT-EARLY)
This is a randomized, double-blind study comparing ABT-494 monotherapy to Methotrexate (MTX) monotherapy in MTX-naïve subjects with moderately to severely active rheumatoid arthritis.
Added 7 months ago
Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide
This is a multi-center, randomized, double-blind, parallel group, active comparator controlled trial to evaluate the efficacy and safety of a single injection of Cingal for the relief of joint pain in subjects with OA of the knee.
Added 7 months ago
A Study in Moderate to Severe Rheumatoid Arthritis Participants (RA-BUILD)
The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily (QD) is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis ...
Added 1 year ago
Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.
Anakinra is a biologic response modifier that competitively antagonises the biologic effects of interleukin-1, the ancestor pleiotropic proinflammatory cytokine produced...
Added 2 years ago
Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis.
The aim of this article was to review the available literature data on SC MTX treatment of inflammatory arthritis, with special emphasis on RA and psoriasis, examining differences with oral MTX treatment.
Added 7 months ago
Prediction of response to methotrexate in rheumatoid arthritis.
This narrative review seeks to cover various genotypic and phenotypic characteristics that have been investigated as predictors of treatment response to MTX in RA.
Added 7 months ago
Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis.
Rheumatoid arthritis patients have a high level of pro-inflammatory interleukin-1. Augmenting the blockade of interleukin-1 receptors by external interleukin-1 receptor antagonist modifies the progression of the disease.
Added 9 months ago
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.
Added 7 months ago
EULAR revised recommendations for the management of fibromyalgia
Fibromyalgia is common with a prevalence of 2% in the general population.1 ,2 However, its diagnosis and management remain a challenge for patients and healthcare professionals.
Added 7 months ago
Spondyloarthritis in over 16s: diagnosis and management
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice...
Added 8 months ago
BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics
These guidelines provide evidence-based guidance for UK clinicians prescribing biologics for adult patients with axSpA. This includes the criteria for starting treatment, the choice of drug and assessing response to treatment.
Added 10 months ago
BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs
The purpose of this guideline is to provide up-to-date, evidence-based recommendations for the safe use of non-biologic DMARDs in adults (>16 years old).
Added 10 months ago
More information
Category | Value |
---|---|
Orphan designation | No |
Type | POM |
Marketing authorisation holder | Amdipharm UK Limited |